Acupuncture and Moxibustion Enter the Prediabetes Conversation
Prediabetes sits in a difficult clinical space: common, often silent, and biologically unstable. It is not a benign label. The condition marks a transition between normoglycemia and type 2 diabetes mellitus, but it also carries cardiometabolic risk long before overt diabetes appears, which is why prevention strategies have drawn so much attention from clinicians and researchers alike.
A recent review in International Journal of General Medicine examines where acupuncture and moxibustion may fit into that prevention effort. The paper treats these approaches not as folkloric add-ons, but as interventions with a growing mechanistic and clinical literature behind them. Across randomized trials and meta-analyses, acupuncture-related therapies have been associated with reductions in fasting blood glucose, postprandial glucose, and HbA1c, along with improvements in insulin resistance and markers tied to β-cell function.
One sentence captures the clinical appeal: prediabetes is metabolically active, and so are the interventions being studied for it.
Why Prediabetes Is More Than a Borderline Lab Result
The review places heavy emphasis on the biology of prediabetes because the disease state is not uniform. Hepatic insulin resistance tends to dominate impaired fasting glucose, while skeletal muscle insulin resistance is more prominent in impaired glucose tolerance. In practice, that means one patient may drift upward through fasting dysregulation while another shows abnormal postprandial handling first. The paper also links progression risk to β-cell dysfunction, chronic low-grade inflammation, mitochondrial dysregulation, lipotoxicity, and multi-organ crosstalk.
That mechanistic framing matters because it helps explain why a single pharmacologic lever often struggles to address the whole syndrome. If insulin resistance, neuroendocrine stress responses, adipokine signaling, and islet exhaustion all move together, then a multimodal therapy becomes biologically plausible. The review argues that acupuncture and moxibustion may exert effects across several of those systems at once rather than through a single isolated pathway.
Clinical Signals Across Trials and Meta-Analyses
The strongest clinical claim in the review is not that acupuncture cures prediabetes, but that trial data increasingly point to measurable metabolic effects. Studies summarized in the paper reported improvements in glycemic endpoints, including fasting glucose, postprandial glucose, and HbA1c. Other findings included better insulin sensitivity and changes in leptin signaling, suggesting that the therapy may influence both glucose homeostasis and appetite-related metabolic regulation.
The review also describes neuroendocrine pathways that could help account for these effects. The vago-islet axis and the hypothalamic-pituitary-adrenal axis appear in the mechanistic discussion as plausible routes through which stimulation at acupoints could influence pancreatic secretion, stress physiology, and broader metabolic balance. In that model, peripheral stimulation does not remain peripheral. It engages autonomic and endocrine circuitry that reaches the islet, liver, and muscle.
A practical bedside implication follows from that framework. If an intervention can shift glucose regulation without requiring escalation to more intensive drug therapy, it may be most useful early in the dysglycemic trajectory, before β-cell failure becomes entrenched.
Modalities Under Study and Safety Profile
The paper does not restrict itself to one form of traditional therapy. It discusses electroacupuncture, Zhuang medicine scraping combined with blood-letting, and auricular acupoint embedding as examples of evolving protocols with reported clinical benefit. These methods differ in technique, but they share a common goal: repeated neuromodulatory input that may influence metabolic control over time.
Safety is one of the more clinically reassuring themes in the review. The therapies are described as favorable from a safety standpoint, which is relevant in prediabetes because many patients have not yet crossed into a stage where long-term drug treatment feels inevitable. A low-risk intervention with repeated exposure potential could be appealing in primary care, community medicine, and integrative treatment settings.
Still, the evidence base is uneven. Small sample sizes, methodological heterogeneity, and limited long-term follow-up remain persistent problems. Those weaknesses make it difficult to determine how durable the glucose improvements are, which subgroups benefit most, and how the results compare with standard lifestyle intervention over months or years rather than weeks.
Screening Uncertainty Shapes the Treatment Debate
The review also returns to a quieter but important problem: prediabetes itself is not diagnosed with perfect consistency. Fasting glucose, HbA1c, and postprandial glucose do not always identify the same patients, and concordance across these measures remains low in some settings. Inter-ethnic variability further complicates screening thresholds and interpretation.
That diagnostic ambiguity affects therapeutic research directly. If trial populations differ in how prediabetes is defined, then pooled results can blur together patients with distinct metabolic phenotypes. A therapy may look more effective in one subgroup than another simply because the underlying biology differs at baseline. Standardization of definitions will therefore matter just as much as refinement of the intervention itself.
The Research Agenda Still Needs Harder Endpoints
The review closes with a clear call for larger multicenter trials, standardized clinical protocols, and multi-omics work to unpack the biology more precisely. Those are sensible priorities. Large studies would help resolve whether glucose improvements are reproducible across settings, while mechanistic profiling could clarify whether changes in inflammation, endocrine signaling, or cellular metabolism drive the clinical effect.
Long-term outcomes remain the real test. HbA1c changes and short-term insulin resistance markers are useful, but prevention medicine ultimately asks a harder question: does the intervention slow conversion from prediabetes to type 2 diabetes, and can it do so safely and consistently enough to matter at scale?
Until those data arrive, acupuncture and moxibustion belong in the category of biologically plausible, increasingly studied, but still incompletely validated options for prediabetes. The review makes the case that they deserve serious scientific attention, not blanket dismissal. It also makes plain where the field is still thin: standardized enrollment criteria, durable follow-up, and sufficiently powered trials that can separate signal from enthusiasm.